[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642777":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":60,"collaborators":27,"id":63,"slug":27,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":27,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":50,"whyStopped":27,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Evolocumab Plus Standard Lipid-Lowering Therapy","EXPERIMENTAL","Participants randomized to this arm will receive early evolocumab in addition to standard-of-care lipid-lowering therapy after successful percutaneous coronary intervention for acute coronary syndrome. Participants will undergo serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to evaluate changes in non-culprit coronary plaque burden, stenosis severity, and high-risk plaque features.",[13,14],"Drug: Evolocumab","Diagnostic Test: Serial photon-counting coronary computed tomography angiography",{"label":16,"type":17,"description":18,"interventionNames":19},"Active Comparator: Standard Lipid-Lowering Therapy","ACTIVE_COMPARATOR","Participants randomized to this arm will receive guideline-directed standard-of-care lipid-lowering therapy after successful percutaneous coronary intervention for acute coronary syndrome. Participants will undergo serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to evaluate changes in non-culprit coronary plaque burden, stenosis severity, and high-risk plaque features.",[14,20],"Drug: Standard Lipid-Lowering Therapy",[22,28,33],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Evolocumab","Evolocumab will be administered early after randomization in participants assigned to the experimental arm, in addition to standard-of-care lipid-lowering therapy. The treatment is intended to achieve intensive low-density lipoprotein cholesterol reduction and to evaluate its effect on coronary plaque progression or stabilization over 52 weeks.",[9],null,{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":27},"DIAGNOSTIC_TEST","Serial photon-counting coronary computed tomography angiography","All participants will undergo photon-counting coronary computed tomography angiography at baseline and at 52 weeks. Imaging will be used to assess changes in total atherosclerotic volume, stenosis severity, and high-risk plaque features in non-culprit coronary vessels.",[16,9],{"type":23,"name":34,"description":35,"armGroupLabels":36,"otherNames":27},"Standard Lipid-Lowering Therapy","Participants will receive guideline-directed standard lipid-lowering therapy according to contemporary clinical practice and investigator judgment.",[16],[38],{"name":39,"affiliation":5,"role":40},"Yong He","STUDY_DIRECTOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":27,"email":46},"Xiaoyu Wang","CONTACT","86+18384252874","wxy2cd@yeah.net",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":27,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":27},"West China Hospital of Sichuan University","RECRUITING","Chengdu","Sichuan","China",{"type":55,"coordinates":56},"Point",[57,58],104.06667,30.66667,{"lat":58,"lon":57},{"type":61,"investigatorFullName":39,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Professor","100642777",false,"NCT07612774","CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS","A Single-center, Randomized Controlled Comparison of Effect of Evolocumab Versus Standard Lipid Lowering Therapy on Plaque Progression in Patients With Acute Coronary Syndrome by Serial PCCT(CAPRA-EVO Trial)","CAPRA-EVO","Inclusion Criteria:\n\nEligible patients must meet the following criteria:\n\n* Age between 40 and 75 years.\n* Diagnosis of ACS, including ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) or unstable angina (UA).\n* Successful PCI treatment, with post-procedural TIMI grade 3 flow and residual stenosis \\\u003C30% and atherosclerotic plaque presence in non-culprit coronary vessels (not attributed to this target event).\n* Suboptimal LDL-C control: Patients must have received any statin treatment for at least 4 weeks, with an LDL-C level ≥1.8 mmol\u002FL; or Statin-naive patients must have an LDL-C level ≥3.2 mmol\u002FL.\n* Agreement to complete baseline CCTA and laboratory tests within 7 days of enrollment and signed informed consent.\n* Commitment to complete 52 weeks of follow-up.\n\nExclusion Criteria:\n\n* History of coronary artery bypass grafting (CABG).\n* History of valve surgery.\n* History of PCI treatment before the index ACS event\n* Complex bifurcation lesions (Medina 1,1,1).\n* Use of PCSK9 inhibitors (e.g., evolocumab, alirocumab) or potent CYP3A4 inhibitors (e.g., itraconazole) within the last 12 months.\n* Known intolerance to statins, evolocumab, or other investigational drugs related to the study.\n* Hepatic or renal insufficiency (eGFR \\\u003C60 mL\u002Fmin\u002F1.73m² or ALT\u002FAST \\>3 times the upper limit of normal).\n* Active autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).\n* Uncontrolled heart failure (NYHA class III-IV) or malignant arrhythmias.\n* Known allergy or hypersensitivity to iodinated contrast media\n* Hyperthyroidism or active thyroid disease\n* Pregnancy or breastfeeding (or plans for pregnancy within the next year).\n* Life expectancy of less than 1 year (e.g., due to advanced malignancy).\n* Participation in another interventional clinical trial within the past 3 months.","ALL","40 Years","75 Years",{"count":74,"type":75},233,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The CAPRA-EVO trial is a single-center, randomized, open-label study with blinded endpoint assessment comparing early evolocumab plus standard lipid-lowering therapy versus standard-of-care lipid-lowering therapy in patients with acute coronary syndrome after successful percutaneous coronary intervention. The study will use serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to assess changes in non-culprit coronary plaque burden and stenosis severity. Secondary outcomes include changes in high-risk plaque features, lipid and inflammatory biomarkers, cardiovascular events, and safety outcomes. The trial aims to determine whether early intensive LDL-C lowering with evolocumab can reduce coronary plaque progression and support PCCT-CCTA as a noninvasive tool for monitoring atherosclerotic plaque dynamics.",[81,82],"Coronary","Coronary Artery Disease",[84,85,86,87],"acute coronary syndrome","coronary computed tomography angiography","proprotein convertase subtilisin\u002Fkexin type 9","randomized controlled trial","2026-06-05",{"date":90,"type":91},"2026-06-09","ACTUAL",{"date":93,"type":75},"2026-05-19",{"date":95,"type":75},"2029-01-31",{"name":5,"class":6},1]